Global EditionASIA 中文双语Français
Home / Business / The Third China International Import Expo

Takeda set to unveil slew of innovative medicines in China

By He Wei in Shanghai | | Updated: 2020-11-09 15:40
Share - WeChat

Global biopharmaceutical company Takeda plans to introduce more than 15 innovative medicines in China in the next five years as part of its commitment to support the "Healthy China 2030" initiative.

The company estimated that these medicines will benefit around 10 million patients suffering from complex and rare diseases in China.

"We remain highly optimistic about China's pharmaceutical market," said Sean Shan, president of Takeda China, during the 3rd China International Import Expo. "The rapid recovery of the Chinese economy from the COVID-19 pandemic has confirmed the close connection between public health and economic development."

One highlight of Takeda's exhibition at the CIIE is the range of new products that are expected to be approved in China soon. These products are mainly related to the field of rare diseases, such as hereditary angioedema and the Gaucher disease.

Takeda has also joined hands with world-leading plasma companies to set up the CoVIg-19 Plasma Alliance to help develop a potential plasma-derived therapy for people at risk of serious complications from COVID-19.

"The hosting of the CIIE has forged a global, innovative ecosystem of circulation," Shan said. "We will continue to invest in China to introduce more global debuts and innovative therapies."

Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349